All In Biotech

BLA 125058 · Biomarin

Aldurazyme

Laronidase · Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 14, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Apr 30, 2003

Approved uses

3

Original approval plus efficacy supplements

Registered trials

18

4 Phase 3, 1 recruiting

FAERS reports

4,133

2,841 serious, 671 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS, and ACUTE RESPIRATORY COMPLICATIONS ASSOCIATED WITH ADMINISTRATION WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS, and ACUTE RESPIRATORY COMPLICATIONS ASSOCIATED WITH ADMINISTRATION See full prescribing information for complete boxed warning . Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available. If a severe hypersensitivity reaction occurs, discontinue ALDURAZYME immediately and initiate appropriate medical treatment. ( 5.1 ) Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions and require additional monitoring. Appropriate respiratory support should be available during infusion. ( 5.2 ) Hypersensitivity Reactions...

What it is approved for

From the label in effect Sep 11, 2026.

ALDURAZYME ® is indicated for the treatment of: adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and patients with the Scheie form of MPS I who have moderate to severe symptoms. ALDURAZYME is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for the treatment of adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for the treatment of patients with the Scheie form of MPS I who have moderate to severe symptoms. ( 1 ) Limitations of Use: The risks and benefits of treating mildly affected patients with the Scheie form have not been established. ( 1 ) ALDURAZYME has not been evaluated for effects on the central nervous system manifestations of the disorder. ( 1 ) Limitations of Use The safety and effectiveness of treating mildly affected patients with the Scheie form have not been established. The effect of ALDURAZYME on central nervous system manifestations of the disorder has not been determined.

Mechanism: Mucopolysaccharide storage disorders are caused by the deficiency of specific lysosomal enzymes required for the catabolism of glycosaminoglycans (GAG). Mucopolysaccharidosis I (MPS I) is characterized by the deficiency of α-L-iduronidase, a lysosomal hydrolase which catalyzes the hydrolysis of terminal α-L-iduronic acid residues of dermatan sulfate and heparan sulfate. Reduced or absent α-L-iduronidase activity results in the accumulation of the GAG substrates, dermatan sulfate and heparan sulfate, throughout the body and leads to widespread cellular, tissue, and organ dysfunction. The...

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 20, 2009 Supplement 161 · Efficacy OrphanLetterLabel
  • May 20, 2009 Supplement 160 · Efficacy OrphanLabelLetter
  • Apr 30, 2003 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLetterLabel
1 products under this application
  • ALDURAZYME · LARONIDASE 2.9MG/ML · VIAL, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Laronidase" as an intervention, any sponsor and status, largest first.

All 18 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia517
  • pneumonia246
  • vomiting207
  • dyspnoea198
  • malaise190
  • cough187
  • fatigue151
  • death141
  • headache133
  • influenza131
  • pain128
  • condition aggravated127

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200481
200560
200628
2007111
200861
200959
201051
201173
201290
2013132
2014133
2015208
2016249
2017264
2018325
2019261
2020259
2021317
2022353
2023371
2024257
2025202
2026188

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Aldurazyme (Laronidase)

2024 spending

$7.4M

Beneficiaries

11

162 claims

Per beneficiary

$672,291

$214.54 per unit

View as table
YearSpending
2020$4,500,167
2021$7,750,225
2022$8,107,409
2023$7,301,136
2024$7,395,200

Part B: Aldurazyme (Laronidase) · HCPCS J1931

2024 spending

$784K

Beneficiaries

n/a

64 claims

Per beneficiary

n/a

2024 ASP limit $38.05 per unit

View as table
YearSpending
2020$1,253,058
2021$1,525,481
2022$903,985
2023$1,026,704
2024$784,277

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 27 on PubMed

Sponsor: BioMarin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.